152 related articles for article (PubMed ID: 11464883)
21. Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
Levi M; DeRemer SJ; Dou C; Ensminger WD; Smith DE
Biopharm Drug Dispos; 2004 Jan; 25(1):27-35. PubMed ID: 14716750
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of amifostine and its metabolites in patients.
Korst AE; Eeltink CM; Vermorken JB; van der Vijgh WJ
Eur J Cancer; 1997 Aug; 33(9):1425-9. PubMed ID: 9337685
[TBL] [Abstract][Full Text] [Related]
23. In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity. implications in cancer chemotherapy.
Das B; Yeger H; Baruchel H; Freedman MH; Koren G; Baruchel S
Eur J Cancer; 2003 Nov; 39(17):2556-65. PubMed ID: 14602142
[TBL] [Abstract][Full Text] [Related]
24. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Selvaggi G; Belani CP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
[TBL] [Abstract][Full Text] [Related]
25. Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group.
Pinkerton CR; Zucker JM; Hartmann O; Pritchard J; Broadbent V; Morris-Jones P; Breatnach F; Craft AE; Pearson AD; Wallendszus KR
Br J Cancer; 1990 Aug; 62(2):319-23. PubMed ID: 2386751
[TBL] [Abstract][Full Text] [Related]
26. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Capizzi RL
Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
[TBL] [Abstract][Full Text] [Related]
27. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
Lorusso D; Ferrandina G; Greggi S; Gadducci A; Pignata S; Tateo S; Biamonte R; Manzione L; Di Vagno G; Ferrau' F; Scambia G;
Ann Oncol; 2003 Jul; 14(7):1086-93. PubMed ID: 12853351
[TBL] [Abstract][Full Text] [Related]
28. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy.
Keshelava N; Seeger RC; Reynolds CP
Eur J Cancer; 1997 Oct; 33(12):2002-6. PubMed ID: 9516842
[TBL] [Abstract][Full Text] [Related]
29. Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora JA; Siden R
Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
[TBL] [Abstract][Full Text] [Related]
30. A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
Fernandez MC; Krailo MD; Gerbing RR; Matthay KK
Cancer; 2000 Jun; 88(12):2838-44. PubMed ID: 10870069
[TBL] [Abstract][Full Text] [Related]
31. Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study.
Späth-Schwalbe E; Lange C; Genvresse I; Krüger L; Eucker J; Schweigert M; Sezer O; Budach V; Possinger K
Anticancer Drugs; 2002 Apr; 13(4):395-403. PubMed ID: 11984085
[TBL] [Abstract][Full Text] [Related]
32. Amifostine: potential for clinically useful cytoprotection.
Budd GT; Lorenzi V; Ganapathi R; Adelstein D; Pelley R; Olencki T; McLain D; Bukowski RM
Support Care Cancer; 1994 Nov; 2(6):380-4. PubMed ID: 7858931
[TBL] [Abstract][Full Text] [Related]
33. A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
Ozkaynak MF; Sahdev I; Gross TG; Levine JE; Cheerva AC; Richards MK; Rozans MK; Shaw PJ; Kadota RP
J Pediatr Hematol Oncol; 2008 Mar; 30(3):204-9. PubMed ID: 18376282
[TBL] [Abstract][Full Text] [Related]
34. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
35. Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines.
Michieli M; Michelutti A; Damiani D; Ermacora A; Masolini P; Stocchi R; Russo D
Leuk Lymphoma; 2001 Aug; 42(4):721-9. PubMed ID: 11697502
[TBL] [Abstract][Full Text] [Related]
36. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies.
Capizzi R
Semin Oncol; 1996 Aug; 23(4 Suppl 8):2-17. PubMed ID: 8783661
[TBL] [Abstract][Full Text] [Related]
37. In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.
Pierelli L; Scambia G; Fattorossi A; Bonanno G; Battaglia A; Perillo A; Menichella G; Panici PB; Leone G; Mancuso S
Br J Cancer; 1998 Oct; 78(8):1024-9. PubMed ID: 9792145
[TBL] [Abstract][Full Text] [Related]
38. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
39. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.
Santana VM; Schell MJ; Williams R; Bowman LC; Thompson EI; Brenner MK; Mirro J
Bone Marrow Transplant; 1992 Nov; 10(5):457-62. PubMed ID: 1464010
[TBL] [Abstract][Full Text] [Related]
40. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]